Best Cell & Gene Therapy CDMOs in United Kingdom
· updated as new inspection, certificate, and trial data enters the platform
20
CDMOs tracked
16
Fully scored
6
With FDA records
23
FDA inspections
69
EMA/MHRA GMP certs
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 12 NAI (no action), 11 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (49), United States (18), Ireland (8), France (7), United Kingdom (4).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 3 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 4 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 5 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 6 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 7 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| 8 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 9 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 10 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 11 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 12 |
SY
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 9 GMP | — | 0 programs |
| 13 |
HH
HiTech Health
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 14 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 15 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 16 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Spur Therapeutics
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Genzyme (Sanofi)
Cambridge, MA (division of Sanofi, HQ: Paris, France)
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
How has post-Brexit MHRA / EMA divergence affected UK CDMO selection?
Since 1 January 2021 the UK has operated MHRA as an independent regulator distinct from EMA. Practically this means: (1) UK manufacturing for EU-market supply requires a separate EMA GMP certificate, held by an EU-based Qualified Person; (2) EU manufacturing for UK-market supply requires MHRA acceptance, though MHRA has continued to recognize EMA GMP inspections under transitional arrangements; (3) the batches themselves may need to be released twice (once by an EU QP for EU supply, once by a UK QP for UK supply). CDMOs with UK + EU footprints are increasingly common in response; UK-only CDMOs need to arrange separate EU QP release for European supply. The Signal Score's Quality Compliance pillar captures both MHRA and EMA GMP certificates, so dual-jurisdiction CDMOs typically rank higher on this pillar.
Which UK CDMOs also cover FDA (US) regulatory geography?
UK CDMOs with US FDA inspection history qualify to supply US-market programs; those without FDA posture are limited to UK + EU. British CDMOs with FDA inspection density typically rank higher on the Signal Score's Quality Compliance pillar because that pillar aggregates FDA + EMA + MHRA data directly. Cross-check with the US region ranking — CDMOs appearing on both UK and US rankings have demonstrated multi-jurisdictional inspection posture, which materially reduces regulatory tech-transfer risk for programs supplying both markets.
How CDMO Signal identifies UK manufacturing presence
UK region attribution derives from each CDMO's declared facility locations. A location string containing UK-specific tokens (England, Scotland, Wales, Northern Ireland, London, Oxford, Cambridge, Liverpool, Manchester, Edinburgh, or 'UK'/'United Kingdom') places the CDMO in the UK region. Multi-site CDMOs appear in every applicable region — a Cambridge + Basel + Boston CDMO shows on UK, Europe, Switzerland, and USA rankings. Sponsors evaluating for a specific program should verify facility-level detail on the individual CDMO profile page — a CDMO with UK presence may only run some processes there and route others through their non-UK sites.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Thermo Fisher Scientific, Oxford Biomedica, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 6 Cell & Gene Therapy CDMOs with FDA inspection records and 69 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities